News from pharmathene, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 05, 2015, 17:00 ET

PharmAthene Reports Second Quarter 2015 Financial and Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its...

May 07, 2015, 16:01 ET

PharmAthene Reports First Quarter 2015 Financial and Operational Results

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Apr 13, 2015, 08:03 ET

PharmAthene Receives $5.8 Million Payment From BARDA

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that on April 9, 2015, it received from the Biomedical Advanced Research and Development...

Mar 09, 2015, 16:00 ET

PharmAthene Reports Year-End 2014 Financial And Operational Results; Announces Plan To Realign Operational Resources

  2014 Operational Highlights - Delaware Court of Chancery issues final judgment granting lump sum award to PharmAthene totaling...

Feb 02, 2015, 10:15 ET

PharmAthene rPA Antigen Formulated With DepoVax™ Demonstrates Promise As Single Unit Dose Anthrax Vaccine

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that its recombinant Protective Antigen (rPA) was one of the vaccines reported by...

Jan 15, 2015, 16:08 ET

PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the...

Jan 07, 2015, 14:18 ET
Nov 20, 2014, 10:15 ET

PharmAthene Fulfills Valortim® IDIQ Contract

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats,...

Nov 06, 2014, 16:02 ET

PharmAthene Provides Third Quarter 2014 Operational And Financial Update

Recent Operational Highlights - Awarded NIAID contract for next generation anthrax vaccine program valued up to $28.1 million -...

Oct 08, 2014, 12:30 ET

PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment

 PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially...

Sep 10, 2014, 09:03 ET

PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Sep 09, 2014, 09:03 ET

New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®

PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were...

Sep 08, 2014, 12:33 ET

PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Sep 08, 2014, 10:13 ET

PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs

 PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have...

Aug 10, 2014, 07:13 ET

Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and...

Aug 04, 2014, 16:02 ET

PharmAthene Reports Second Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Jun 09, 2014, 10:30 ET

PharmAthene Granted U.S. Patent For Recombinant Bioscavenger

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to...

Jun 04, 2014, 10:30 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014...

May 29, 2014, 10:29 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax® anthrax vaccine program were presented...

May 08, 2014, 16:02 ET

PharmAthene Reports First Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...